LigaChem Bio partner Iksuda reports 50% ORR for IKS014 in breast cancer

Iksuda Therapeutics, a partner of LigaChem BioScience, has reported positive Phase 1 interim results for IKS014, a HER2-targeted antibody-drug conjugate (ADC) for patients with HER2-positive breast cancer who have previously received Enhertu treatment.

In the clinical study, 5 out of 10 evaluable patients achieved a partial response, resulting in an objective response rate (ORR) of 50%. These patients had undergone a median of six prior treatments. Notably, some patients showed tumor reduction even after disease progression on Enhertu, with some maintaining responses for over 18 months.

IKS014 utilizes LigaChem Bio’s ConjuAll platform, which features a unique payload mechanism designed to overcome resistance to TOP1i-class ADCs like Enhertu. Regarding safety, the study reported a 15.2% rate of Grade 3 treatment-related adverse events among 105 participants, with no reported Grade 5 or serious treatment-related adverse events.

Detailed results will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December. LigaChem Bio has licensed the rights for IKS014 to Iksuda for global markets excluding Korea and Greater China, while Fosun Pharma holds the rights for Greater China.